Illumina, Inc. announced today that Caroline Dorsa has joined the company’s Board of Directors. Given her financial expertise, Ms. Dorsa will also participate on the Audit Committee of the Board.
Ms. Dorsa has held a number of senior management positions at Merck & Co., Inc., including Senior Vice President of Marketing Strategy and Integration, and Vice President and Treasurer, where she also oversaw investor relations, financial planning for manufacturing and tax. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development, and investor relations teams. She is a Director of Biogen Inc. and Intellia Therapeutics, Inc., and a trustee of the Goldman Sachs MLP Income Opportunities Fund and the Goldman Sachs MLP and Energy Renaissance Fund.
“Caroline brings a great breadth of knowledge and experience as a director on major boards and a senior executive at large companies,” said Francis deSouza, Illumina President and Chief Executive Officer. “Her deep understanding of the clinical space will enable Caroline to make a significant contribution to Illumina as we continue to pursue growth in our clinical markets.”
In addition to her service at Merck & Co., Inc. and at Public Service Enterprise Group, Ms. Dorsa served as Senior Vice President and CFO of Avaya, Inc. She received her B.A. from Colgate University and her M.B.A. from Columbia University.
Source: Illumina
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.